Evidence map›Paper›PMID 41480384›Full record

ReviewFrontiers in pharmacology2025

Research progress on the regulatory effects and mechanisms of natural active products on intestinal barrier function.

Fuyixuan Zheng, Yuemei Sun, Minghui Zhao, Rong Wang, Wenbin Li

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fuyixuan Zheng *Department of Pharmacy, 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, China.
Yuemei Sun *Department of Pharmacy, 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, China.
Minghui ZhaoDepartment of Pharmacy, 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, China.
Rong WangDepartment of Pharmacy, 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, China.
Wenbin LiDepartment of Pharmacy, 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a key defense line for the body to resist pathogens and maintain internal environment stability, the intestinal barrier is crucial for maintaining human health, and its functional damage is closely related to the occurrence of various intestinal diseases, especially in the hypoxic environment of high altitude, the problem of intestinal barrier damage is more prominent. Natural active products are widely sourced and exhibit unique potential in regulating intestinal barrier function due to their multi-target and low-toxicity characteristics. This article comprehensively reviews the prevention and treatment effects of natural active products on common intestinal diseases and high-altitude intestinal injury, focusing on elucidating the mechanism by which they regulate intestinal barrier function through eight key signaling pathways such as NF-κB, Wnt/β-catenin, and mTOR, in which the HIF family is a key factor in regulating hypoxic stress response, and this signaling pathway is the "lifeline" for cells to cope with hypoxia, emphasizing its application potential in the prevention and treatment of high-altitude intestinal barrier injury, and providing a theoretical basis for the development of natural drugs for high-altitude environments and related intestinal diseases.

Indexed as

Gutmicrobiotahigh altitudeintestinal barrierintestinal diseasesnatural active productssignaling pathway

Identifiers

PMID41480384
PMCPMC12753450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.